Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Burning Rock Biotech's Enterprise Value is €41.02 Mil.
Burning Rock Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-4.28 Mil. Therefore, Burning Rock Biotech's EV-to-FCF for today is -9.59.
The historical rank and industry rank for Burning Rock Biotech's EV-to-FCF or its related term are showing as below:
FRA:6BU0'
s EV-to-FCF Range Over the Past 10 Years
Min: -577.67 Med: -2.88 Max: 3.55
Current: -10.07
During the past 9 years, the highest EV-to-FCF of Burning Rock Biotech was 3.55. The lowest was -577.67. And the median was -2.88.
FRA:6BU0's EV-to-FCF is ranked worse than 100% of 99
companies
in the Medical Diagnostics & Research industry
Industry Median: 26.84
vs FRA:6BU0: -10.07
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Burning Rock Biotech (FRA:6BU0) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Burning Rock Biotech's PE Ratio (TTM) for today is calculated as:
Burning Rock Biotech's share price for today is €8.65.
Burning Rock Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.695.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Burning Rock Biotech EV-to-FCF Related Terms
Burning Rock Biotech EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Burning Rock Biotech's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Burning Rock Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Burning Rock Biotech EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Burning Rock Biotech's EV-to-FCF falls into.
Burning Rock Biotech's current Enterprise Value is €41.02 Mil.
Burning Rock Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Burning Rock Biotech (FRA:6BU0) has a EV-to-FCF of -9.59 as of Jul. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Burning Rock Biotech and its competitors. According to the industry distribution chart, Burning Rock Biotech ranks #999999 out of 99 companies in the Medical Diagnostics & Research industry.
Is Burning Rock Biotech's EV-to-FCF too high?
Burning Rock Biotech's current EV-to-FCF is -9.59. Based on the distribution chart, Burning Rock Biotech ranks #999999 out of 99 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Burning Rock Biotech has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Burning Rock Biotech's EV-to-FCF compare to XGN and IDXG?
According to the Medical Diagnostics & Research industry distribution chart, Burning Rock Biotech ranks #999999 out of 99 companies for EV-to-FCF. This places Burning Rock Biotech in the lower half of its industry. The industry median EV-to-FCF is 26.84. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 26.84, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Burning Rock Biotech and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 26.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Burning Rock Biotech's current EV-to-FCF is -9.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burning Rock Biotech stock overvalued right now?
Based on GuruFocus' analysis, Burning Rock Biotech (FRA:6BU0) is currently considered Significantly Overvalued. The stock's GF Value™ is €6.42, compared to a current price of €8.65 — trading 34.7% above its estimated fair value. The current EV-to-FCF is -9.59. Burning Rock Biotech's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Burning Rock Biotech (FRA:6BU0), the current EV-to-FCF is -9.59 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Burning Rock Biotech (FRA:6BU0) Overvalued in 2026?
Based on GuruFocus' analysis, Burning Rock Biotech stock appears to be overvalued.
The current stock price of €8.65 is trading 34.7% above its estimated GF Value™ of €6.42.
GuruFocus considers Burning Rock Biotech to be Significantly Overvalued.
Key valuation signals for FRA:6BU0:
EV-to-FCF: -9.59
GF Value™: €6.42 vs. price of €8.65 (34.7% above fair value)
No single metric tells the full story. See the FRA:6BU0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
59GF Score
Get the complete analysis for FRA:6BU0
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6BU0 has been successfully added to your 
